Biotechnology Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025